WBA - Walgreens Boots Alliance, Inc.

Better Buy: CVS vs. Walgreens Stock

The competition in retail pharmacy is intense. Neither of these stocks has been a winner for investors over the last 12 months. Here's how two Motley Fool contributors think CVS and Walgreens stack up against each other.

Walgreens (WBA) Upgraded to Buy: Here's What You Should Know

Walgreens (WBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

• 
  All You Need to Know About NetEase (NTES) Rating Upgrade to Strong Buy

  Zacks
• 
  All You Need to Know About Akerna Corp. (KERN) Rating Upgrade to Buy

  Zacks

Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes

Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.

• 
  Factors to Know Ahead of Ollie's Bargain (OLLI) Q1 Earnings

  Zacks
• 
  Factors Setting the Tone for Vail Resorts' (MTN) Q3 Earnings

  Zacks

Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know

Walgreens Boots Alliance (WBA) closed the most recent trading day at $30.32, moving -0.16% from the previous trading session.

• 
  Cadence Design Systems (CDNS) Stock Sinks As Market Gains: What You Should Know

  Zacks
• 
  Texas Instruments (TXN) Gains But Lags Market: What You Should Know

  Zacks

3 Numbers That Could Make You Think Twice About Walgreens' Dividend

Investors may want to resist the temptation to load up on a dividend that could end up being too good to be true.

3 Top Stocks That Just Went on Sale

Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.

Walgreens Just Got Another Piece of Bad News -- Should You Sell Its Stock?

The problem this time around is another instance of one of the company's bugbears over the last few years: legal settlements pertaining to its filling of opioid drug prescriptions. The latest piece of bad news is that Walgreens agreed on May 17 to a $230 million settlement with the city of San Francisco, which was suing it for lack of sufficient due diligence when it filled prescriptions for opioid medications.

Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know

In the latest trading session, Walgreens Boots Alliance (WBA) closed at $30, marking a +0.1% move from the previous day.

• 
  McDonald's (MCD) Stock Sinks As Market Gains: What You Should Know

  Zacks
• 
  Nike (NKE) Outpaces Stock Market Gains: What You Should Know

  Zacks

Boots boss more than doubles pay to £3.8m as chain triples profits

Chemist made a profit of £137m in year to 31 August, helped by closure of 44 underperforming stores

Pharmacy chain Walgreens Boots Alliance to cut corporate jobs by 10%

Walgreens Boots Alliance Inc said on Friday it would slash its corporate staff by about 10%, as it streamlines operations and focuses on consumer-facing healthcare businesses.

Wall Street Expects This Stock to Skyrocket 30%. Is That Realistic?

Shares of the pharmaceutical services leader have fallen close to 17% so far this year while the S&P 500 has risen nearly 8%. Walgreens could be poised to rebound, though. Wall Street expects the stock to skyrocket by 30%.

3 Iconic Dow Stocks That Can Safely Double Your Money by 2028

The Dow Jones Industrial Average is composed of 30 time-tested, multinational businesses. Three of them are capable of delivering triple-digit total returns over the next five years.

Walgreens fights 'staggering' $642 million arbitration award to Humana

National retail pharmacy giant Walgreen Co has asked a U.S. judge to vacate an arbitrator's award of more than $642 million to Humana Health Plan Inc in a drug-pricing dispute, calling the "staggering" sum the result of a "miscarriage of justice." Lawyers for Walgreens made their legal challenge in a filing on Friday in Washington, D.C., federal court, in a clash over prescription drug reimbursement contracts between Walgreens and Humana. Separately, Humana asked the U.S. court to confirm the award.

Is Walgreens Boots Alliance Stock a Buy Now?

Household name and dividend growth stock Walgreens Boots Alliance (NASDAQ: WBA) hasn't been good to shareholders for some time now. Walgreens is transitioning its business beyond prescriptions and retail stores and is working through a bloated balance sheet from an acquisition spree over the past few years. Here is where Walgreens stands and whether you should consider buying shares or wait it out.

Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?

The Dow Jones Industrial Average was the best-performing of the three major indexes in 2022, but 2023 hasn't been as kind to the blue chip index. The regional banking crisis has hit the Dow hard, and the rebound in tech stocks has also left it lagging behind the S&P 500 and Nasdaq Composite, which have more exposure to the tech sector. As you can see from the chart below, the Dow is actually down slightly for the year even as the other two indexes have delivered solid gains.

Can Walgreens Succeed in This Market Where CVS Failed?

When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?

Could Walgreens Boots Alliance Stock Help You Become a Millionaire?

The stock doesn't have a great track record, but could that change as it pivots toward healthcare?

Walgreens reaches $230 million opioid settlement with San Francisco

(Reuters) -San Francisco said on Wednesday it reached a $230 million settlement with Walgreens Boots Alliance Inc over its role in the city's opioid epidemic. The settlement came nine months after U.S. District Judge Charles Breyer in San Francisco said the drugstore chain could be held liable for having "substantially contributed" to an opioid epidemic that caused "widespread harm" in the city and constituted a public nuisance. Breyer faulted Walgreens for its "15-year failure" to properly scrutinize opioid prescriptions and flag possible misuse of the sometimes highly addictive drugs.

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow?

Whether or not you buy the highest-yielding Dow stocks depends on how you invest. Here is a look at each of them.

Walgreens sees benefit from CVS exiting clinical trial business

Walgreens remains bullish on its clinical trials segment as rival CVS announces closure.

Walgreens sells some AmerisourceBergen shares for $694 million

AmerisourceBergen will repurchase about $50 million of its common stock from Walgreens in this transaction, the U.S. drugstore chain said, adding that its ownership of AmerisourceBergen's common stock would remain at 17%. The Deerfield, Illinois-based company sold AmerisourceBergen shares for $1 billion last December, cutting its ownership from 20%. The share sale has no impact on the long-term partnership between the two companies, Walgreens said.

Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Walgreens Boots Alliance (WBA) closed at $31.17, marking a -1.33% move from the previous day.

• 
  Texas Instruments (TXN) Gains But Lags Market: What You Should Know

  Zacks
• 
  Coca-Cola (KO) Stock Sinks As Market Gains: What You Should Know

  Zacks